This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
New Strong Sell Stocks for March 1st
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
MedTech Thriving on Consolidation & Expansion: Stocks to Buy
by Zacks Equity Research
The industry has some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation.
Key FDA Events to Watch Out for in Jul 2017
by Arpita Dutt
Will the FDA follow the advice of its advisory panel and give its nod to Puma's (PBYI) neratinib?
What Falling Estimates & Price Mean for Eagle Pharmaceuticals (EGRX)
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
MedTech Stocks' Q4 Earnings on Mar 1: ICUI, GKOS & EGRX
by Zacks Equity Research
Let's take a look at the major MedTech stocks within the broader medical community, slated to release their reports on Mar 1.
Falling Earnings Estimates Signal Weakness Ahead for Eagle Pharmaceuticals (EGRX)
by Zacks Equity Research
Eagle Pharmaceuticals (EGRX) should not be considered as it holds an unfavorable Zacks Rank and it has seen negative earnings estimate revisions.
Eagle Pharmaceuticals Wraps Up Ryanodex NDA Submission
by Zacks Equity Research
Eagle (EGRX) announced that it has completed the submission of its 505(b)(2) NDA in the U.S. for Ryanodex for the treatment of exertional heat stroke.
Quest Diagnostics: Strong Q3, Strategic Initiatives Add Value
by Zacks Equity Research
On Dec 27, 2016, we issued an updated research report on Quest Diagnostics, Inc. (DGX).
Myriad Genetics' Unit Releases Favorable Data on Vectra DA
by Zacks Equity Research
Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience released favorable data on the use of Vectra DA to predict treatment response in patients with rheumatoid arthritis (RA).
New Strong Buy Stocks for December 16th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
New Strong Buy Stocks for November 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Wednesday
The Zacks Analyst Blog Highlights: Best Buy, Edgewell Personal Care and Eagle Pharma
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Best Buy, Edgewell Personal Care and Eagle Pharma
New Strong Buy Stocks for November 15th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday
Company News for November 10, 2016
by Zacks Equity Research
Companies in the News are: BDSI,DISH,EGRX,HCAP